ArticleCurrent treatment options in neurology2016
Treatment of Neuromyelitis Optica Spectrum Disorder: Acute, Preventive, and Symptomatic.
Article in Current treatment options in neurology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 67 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
67 citing papers in PubMed, 2 syntheses or guidelines pooled it, 155 citations in OpenAlex.
- Anti-IL-6 Therapies for Neuromyelitis Optica Spectrum Disorders: A Systematic Review of Safety and Efficacy.Current neuropharmacology · 2021Pooled it
- Long-term disability in neuromyelitis optica spectrum disorder with a history of myelitis is associated with age at onset, delay in diagnosis/preventive treatment, MRI lesion length and presence of symptomatic brain lesions.Multiple sclerosis and related disorders · 2019Pooled it
- Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial.The Lancet. Neurology · 2020Trial
- Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial.The Lancet. Neurology · 2020Trial
- Safety and Effectiveness of Inebilizumab in Patients with Neuromyelitis Optica Spectrum Disorder: Interim Analysis of a Post-marketing Surveillance in Japan.Neurology and therapy · 2026Article
- Real-World Investigation of Satralizumab in Patients With Neuromyelitis Optica Spectrum Disease.Annals of clinical and translational neurology · 2026Article
- EEG biomarkers of microstructural damage in normal-appearing white matter among patients with neuromyelitis optica spectrum disorder: A DTI-EEG combined study.Frontiers in immunology · 2026Article
- Multimodal MRI biomarkers and machine learning in neuromyelitis optica spectrum disorder: a review.Frontiers in neurology · 2026Review
- A structured approach for identifying disease analogs for pulmonary arterial hypertension.Journal of managed care & specialty pharmacy · 2025Article
- Factors for Rituximab Refractoriness in AQP4-IgG+ NMOSD: A Cohort Study.Annals of clinical and translational neurology · 2025Article
- Genetic Insights into Therapeutic Targets for Neuromyelitis Optica Spectrum Disorders: A Mendelian Randomization Study.Molecular neurobiology · 2025Article
- Potential drug targets for Neuromyelitis optica spectrum disorders (NMOSD): A Mendelian randomization analysis.PloS one · 2025Article
- Biotinidase Deficiency Induced Optic Neuropathy: A Case Report and Literature Review.Neuro-ophthalmology (Aeolus Press) · 2025Review
- Article
- Eculizumab for the acute attack of neuromyelitis optica spectrum disorder.Frontiers in immunology · 2025Article
- Advances in the treatment of neuromyelitis optic spectrum disorder.Therapeutic advances in neurological disorders · 2025Review
- Article
- Successful Childbirth During Satralizumab Treatment in Neuromyelitis Optica Spectrum Disorder.Cureus · 2024Article
- Use of Complementary and Alternative Medicine in Patients With Idiopathic Inflammatory Demyelinating Diseases of the Central Nervous System: A Cross-Sectional Study in Thailand.Current therapeutic research, clinical and experimental · 2024Article
- Therapeutic inertia in the management of neuromyelitis optica spectrum disorder.Frontiers in neurology · 2024Article
7 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
Abstract
opinion statementNeuromyelitis optica spectrum disorder (NMOSD) is a rare, autoimmune disease of the central nervous system that primarily attacks the optic nerves and spinal cord leading to blindness and paralysis. The spectrum of the disease has expanded based on the specificity of the autoimmune response to the aquaporin-4 water channel on astrocytes. With wider recognition of NMOSD, a standard of care for treatment of this condition has condition based on a growing series of retrospective and prospective studies. This review covers the present state of the field in the treatment of acute relapses, preventive approaches, and therapies for symptoms of NMOSD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.